Understanding Use Of Surrogate Endpoints In Oncology
Welcome to our comprehensive guide on Use Of Surrogate Endpoints In Oncology. Presentation Title:
Key Takeaways about Use Of Surrogate Endpoints In Oncology
- Florian Simon, MD, University Hospital Cologne, Cologne, Germany, summarizes his talk on '
- Speaker: Gabe Sonke, MD, PhD Presented at Session 5: Approaches to shorten phase II studies by the
- surrogate
- Panelists discuss the
- Omali Pitiyarachchi, MBBS, UNSW Sydney, Sydney, Australia, comments on the need for
Detailed Analysis of Use Of Surrogate Endpoints In Oncology
A clinical perspective on Vinay Prasad, MD MPH HemeOnc Doctor & Associate Professor of Epi/ Biostats Host of Plenary Session Podcast ... As more biomarkers and
Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, comments on the potential of cerebrospinal fluid (CSF)-based ...
In summary, understanding Use Of Surrogate Endpoints In Oncology gives us a better perspective.
